Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Headache Pain. 2010 Feb;11(1):33-44. doi: 10.1007/s10194-009-0163-x. Epub 2009 Nov 6.

Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting.

Collaborators (183)

Wegner T, Fischer HW, Wolfram B, Schindlbeck K, Peters S, Schax U, Dietz EM, Haas J, Föh M, Katholnigg D, Rauch G, Kühn M, Becker VU, Springer M, Auner GM, Hontzek K, Kaune HW, Schreibmüller V, Liadski S, Wiedeking B, Rengeling M, Henning V, Walaschewski B, Schätzl RJ, Steinbrück B, Reineke H, Rönnebeck S, Armbruster T, Schätzl RJ, Tiedt A, Hördt T, Eisenkrätzer F, Waldmann R, Sandow P, Metzger B, Eckert A, Kayali N, Lang M, Klein H, Böneke H, Schiel C, Eyck M, Gross HD, Beck A, Spengruber B, Schulz-Meentzen M, Gruber A, Rubbel-Ehle A, Porrmann B, Unger M, Schaps KP, Stienker-Fisse H, Meyer G, Matuschke A, Eckardt H, Jansen U, Klook K, Witteborn M, Roidl T, Farke-Rämer K, Dietlein M, Möller P, Hofmann W, Lederle S, Wiedemann F, Rieser U, Wimmer ML, Enderle C, Gottesbüren D, Weber T, Oberling M, Flöhl W, Martinovic N, Köller W, Jersch B, Adam H, Carstensen O, Franke K, Martini N, Schneider-Nutz H, Bek E, Magnus-Ellenbroek B, Kukowski B, Jorns U, Kelch T, Endrass G, Katzfuss R, Schmitt L, Kühn F, Schietsch HJ, Diery HD, Wiese-Junginger D, Guse-Grosse F, Thonack J, Franz P, Dauwe R, Gerbaulet U, Koller S, Freitag E, Krug R, Jonas B, Linke A, Ulmer A, Jakob S, Gillwald V, Tomm M, Ampatziadis N, Udosic J, Kossler-Wiesweg C, Brose KO, Westfal HP, Noveanu RD, Jacob C, Fuchs V, Althen A, Lang A, Lebmeier R, Beykirch KF, Müller S, Krehan G, Ivancic R, Eichhorn A, Lion F, Misera A, Nowack C, Wagner A, Böger M, Ries S, Hachenberg K, Pickert P, Lang M, Strick V, Lüdtke A, Siemer M, Setiawan S, Feuerstack G, Müller A, Kim-Giesemann S, Noack D, Unsorg B, Busch R, Weischer K, Stenzel C, Albrecht C, Assmann U, Wegner M, Hufnagel H, Loddo M, Lohse LD, Derissen W, Junge B, Seidel F, Bannies H, Hanoldt I, Bachus R, Burger-Deinerth E, Ha-Phuoc H, Gülbeyaz M, Brauer G, Leps W, Ahrari F, Lode S, Brandt C, Zimmermann R, Böhme A, Bruckhaus-Walter M, Phillipp U, Loel U, Bruch M, Schulze K, Kohl SC, Lakony R, Nesimi M, Zug HD, Scarel S, Schultheiss UG, Berdermann-Welz S, Freudenstein W, Schmitt R, Christopher A, Patzelt U, Augustin-Reuss D, Sigel KO.

Author information

  • 1Neurology Outpatient Clinic, St. Elisabeth Krankenhaus Köln, 50935 Cologne, Germany. gereon.nelles@uni-duisburg-essen.de

Abstract

The majority of patients with migraine headaches are treated in non-specialized institutions though data on treatment outcomes are largely derived from tertiary care centers. The current non-interventional study explores efficacy and tolerability outcomes of patients with episodic migraines receiving topiramate as preventive agent in a general practice setting. A total of 366 patients (87% female, mean age 41.8 +/- 11.6 years) were eligible for migraine prevention and treated with flexible dose topiramate for 6 months (core phase), and optionally for a total of 12 months (follow-up phase). Overall, 261 patients (77.7% of safety analysis set, SAF) completed the core phase. Reasons for discontinuation included adverse events (2.1%), lost to follow-up (1.8%), other reasons (1.5%), and end of therapy (0.3%) though in the majority of patients who discontinued no reasons were listed. The median daily dose at endpoint was 50 mg/day (range, 25-187.5 mg/day). The median days with migraine headaches decreased from 6.0 to 1.2 days (p < 0.001), median pain intensity score decreased from 17.0 to 3.2 points (p < 0.001). In women with reported menstruation-associated migraine, the median number of migraine attacks decreased from 4.0 to 0.9 (p < 0.001). Absenteeism as well as triptan use decreased significantly, and significant improvements in activities of daily living and quality of life were reported. The most frequently reported AEs were paraesthesia (4.2%) and nausea (3%). Results suggest that migraine prevention with topiramate in a general practice is generally well tolerated and associated with a significant improvement in migraine headaches and related functional impairment.

PMID:
19894100
[PubMed - indexed for MEDLINE]
PMCID:
PMC3452185
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk